Merck’s stock is falling after a rare revenue miss, and the announcement of a $3 billion cost-cutting plan that will include ...

Merck is undergoing a strategic restructuring, resulting in immediate job cuts in administration, sales, and research as part of a plan to save $3 billion by 2027.

Along with its financial results for the second quarter of 2025, Merck revealed a restructuring plan to save $3 billion by ...

Merck said it is embarking on a multi-year cost-savings plan, which includes cuts to its workforce and real-estate footprint, ...

German drugmaker Merck KGaA on Thursday joined peers in saying it was considering distribution models that serve U.S.

Merck & Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed ...

Merck (NYSE: MRK) has broken ground on a $1 billion facility in Wilmington, Delaware, becoming the latest pharmaceutical company to boost domestic investment as industry-targeted tariffs loom.

The restructuring includes the elimination of certain roles and a reduction in the company’s global real estate footprint.

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its best-selling cancer drug Keytruda to the U.S. and speed future drugs to market.

Merck is seeking confirmation that Bayer is liable for talc claims that have been filed against both companies since 2014 when Bayer bought product lines from Merck in a $14 billion deal. The ...

FRANKFURT, June 6 (Reuters) - The CEO of German technology group Merck KGaA (MRCG.DE) said that unravelling trade ties with China would come at great economic cost and she was banking on dialogue ...